GO
Loading...

Pharmaceuticals

More

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 7:54 AM ET

    Eli Lilly earnings plunged, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year forecast.

  • Inside Eli Lilly's earnings: CEO     Thursday, 23 Oct 2014 | 7:18 AM ET

    John Lechleiter, Eli Lilly CEO, crunches the numbers on his company's quarterly results and explains how a strong dollar is impacting global sales.

  • Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 6:50 AM ET

    Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate production and clinical testing of three...

  • Oct 22- Drugmakers Abbott Laboratories and Mylan Inc on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands. Windau said many investors had feared the new Treasury rules might derail the deal, and they...

  • Oct 22- A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter. Advent and Avista have prevailed in an auction for Kremers Urban, which attracted interest from other private equity firms...

  • *European Commission to provide 100 million euros. The move shows how momentum is building to get medical interventions-- and particularly vaccines-- to West Africa as soon as possible to control the world's worst Ebola outbreak, which, according to official figures, has killed nearly 5,000 people, most of them in Liberia, Sierra Leone and Guinea.

  • Oct 22- Abbott Laboratories and Mylan Inc said on Wednesday they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction. Treasury on Sept. 22 made changes to the corporate tax rules that govern such "inversion" merger...

  • Late Tuesday, both Yahoo Inc and Broadcom beat on revenue. Dow component Boeing edged 0.3 percent higher to $127.50 after its results, while Dow advanced 4 percent to $50.13. Yahoo climbed 5.4 percent to $42.34 while Broadcom added 6.3 percent to $39.70.

  • "Building 1" is already under construction in Basel and at a height of 178 metres will become the country's tallest building when it opens at the end of 2015.. The drugmaker traces its roots in Basel to 1896 when Fritz Hoffman-La Roche set up the business, and it is now one of the world's most successful pharmaceutical companies, whose leading position in cancer...

  • Abbott says third-quarter sales match forecasts Wednesday, 22 Oct 2014 | 8:11 AM ET

    Oct 22- Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc.. Abbott on Wednesday said sales from continuing and discontinued operations rose 4.7 percent to $5.6 billion in the third quarter. That included generic medicines, now...

  • GSK sees first Ebola vaccine doses ready late this year Wednesday, 22 Oct 2014 | 8:08 AM ET

    LONDON, Oct 22- GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production. "I fully anticipate that the initial supply should be available before the year end," Chief Executive Andrew Witty told reporters on Wednesday after reporting...

  • Johnson & Johnson plans Ebola vaccine testing Wednesday, 22 Oct 2014 | 7:42 AM ET

    NEW BRUNSWICK, N.J.— Johnson& Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. Johnson& Johnson also plans to test whether its vaccine protects against the version causing the outbreak, which has killed more than 4,500 people. Johnson& Johnson is developing the vaccine...

  • *J&J says has discussed collaboration with GlaxoSmithKline. Johnson& Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine. The World Health Organization hopes that tens of thousands of people in...

  • J&J, GSK ready to collaborate on Ebola vaccine work Wednesday, 22 Oct 2014 | 6:11 AM ET

    LONDON, Oct 22- Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson& Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its two-step vaccine available next year, said on Wednesday that vaccine makers would...

  • Third Point urges Amgen to consider breakup Tuesday, 21 Oct 2014 | 7:31 PM ET

    A hedge fund run by a famed investor said Tuesday it has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In response, Amgen said that its board and management are continually assessing the company's business. Third Point said Amgen Inc., which makes a range of drugs for arthritis, anemia and other diseases, is not...

  • Study finds drugs still in recalled supplements Tuesday, 21 Oct 2014 | 4:27 PM ET

    Pieter Cohen, an internist and researcher at Cambridge Health Alliance, a Boston- area health care system. The tested supplements were recalled by manufacturers after FDA raised concerns about drugs in their products. "There should be significant legal and financial consequences for manufacturers who the FDA finds to be continuing to sell these spiked...

  • NEW YORK, Oct 20- AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker. Investors were given no advance warning on Thursday, when...